Huh Gene, Ahn Jae-Cheul, Cha Wonjae, Jeong Woo-Jin
Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Gland Surg. 2021 Feb;10(2):721-728. doi: 10.21037/gs-20-741.
Accurate diagnosis of malignancy in the parotid gland before surgery is often challenging. Various clues should be used to increase the index of suspicion for malignancy. We hypothesized that malignant lesions of the parotid gland are located at the superior part of the gland compared to benign ones.
A total of 169 consecutive patients were included in this study whose medical records were retrospectively reviewed. Benign and malignant tumors were compared in size, height difference from five anatomical landmarks: hard palate, mastoid tip, earlobe, condylar head, and mandibular notch. The cutoff heights from significant landmarks (hard palate, condylar head) were estimated with ROC analysis and chi-square test.
Twenty-nine patients (17.2%) were diagnosed with malignant and 140 patients (82.8%) as benign. The height differed significantly between benign and malignant tumors when the reference point was set for the hard palate (P=0.024) and the condylar head (P=0.049), with the cutoff height from reference points to be 22.5, 51.5 mm, respectively. Diagnostic values of parotid level difference presented higher sensitivity (75.9% for hard palate, 72.4% for condylar head 47.8% for fine needle aspiration cytology) and lower false negative rate (24.1% for hard palate, 27.6% for condylar head 52.2% for fine needle aspiration cytology) compared to fine needle aspiration cytology.
Malignant tumors of the parotid gland tend to locate at the superior part of the gland compared to benign tumors. Parotid tumors lying cephalad should raise an index of suspicion for malignancy. Height of the tumor in the parotid gland should be deliberately considered during the first encounter of the patient, which in turn could curate the next step in the diagnostic approach and treatment planning.
术前准确诊断腮腺恶性肿瘤往往具有挑战性。应运用各种线索来提高对恶性肿瘤的怀疑指数。我们推测,与良性病变相比,腮腺恶性病变位于腺体的上部。
本研究共纳入169例连续患者,对其病历进行回顾性分析。比较良性和恶性肿瘤的大小,以及与五个解剖标志(硬腭、乳突尖、耳垂、髁突头和下颌切迹)的高度差异。通过ROC分析和卡方检验估计从重要标志(硬腭、髁突头)的截断高度。
29例(17.2%)患者被诊断为恶性肿瘤,140例(82.8%)为良性肿瘤。当以硬腭(P=0.024)和髁突头(P=0.049)为参考点时,良性和恶性肿瘤的高度差异显著,从参考点的截断高度分别为22.5、51.5毫米。与细针穿刺细胞学检查相比,腮腺水平差异的诊断价值具有更高的敏感性(硬腭为75.9%,髁突头为72.4%,细针穿刺细胞学检查为47.8%)和更低的假阴性率(硬腭为24.1%,髁突头为27.6%,细针穿刺细胞学检查为52.2%)。
与良性肿瘤相比,腮腺恶性肿瘤倾向于位于腺体的上部。位于头侧的腮腺肿瘤应提高对恶性肿瘤的怀疑指数。在首次接诊患者时应仔细考虑腮腺肿瘤的高度,这反过来可以指导诊断方法和治疗计划的下一步。